Clinical Trial Update: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating vutrisiran for transthyretin amyloidosis with cardiomyopathy is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis with Cardiomyopathy

Drugs mentioned

• AMVUTTRA (VUTRISIRAN)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | Status: ENROLLING_BY_INVITATION